Prestige Consumer Healthcare (PBH)
NYSE:PBH
Want to see PBH full AI Analyst Report?
PBH Stock Chart & Stats
$58.13
-$0.15(-0.20%)
At close: 4:00 PM EST
$58.13
-$0.15(-0.20%)
Day’s Range― - ―
52-Week Range$42.62 - $85.57
Previous CloseN/A
Volume57.25K
Average Volume (3M)779.50K
Market Cap
$2.25B
Enterprise Value$3.23B
Total Cash (Recent Filing)$63.87M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)11.9
Beta0.35
Next Earnings
Jul 30, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.94
Shares Outstanding47,372,166
10 Day Avg. Volume637,306
30 Day Avg. Volume779,496
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.30
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue2.97
Enterprise Value/Gross Profit5.50
Enterprise Value/Ebitda9.76
Forecast
1Y Price Target
$82.25Price Target Upside41.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)4.54
Revenue Forecast (FY)$1.19B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowPrestige converts earnings into substantial cash, generating roughly $230–$260M OCF and $246M FCF in FY26. Durable cash generation funds M&A, share repurchases, low capex and deleveraging, giving management flexibility to invest and absorb shocks across economic cycles.
Margin ResilienceHigh mid‑50s gross margins and low‑30s EBITDA reflect pricing power in branded OTC and a focused cost structure. This margin durability supports cash conversion, funds brand investment and limits the dependency on high capex, sustaining long‑term profitability through modest sales volatility.
Scale Via Strategic M&ATargeted deals and the Pillar5 acquisition increase category scale, international exposure and vertical control in eye care. Combined with e‑commerce penetration (~18%), these moves diversify revenue mix, create integration synergies and provide a structural pathway to the company’s multi‑year growth targets.
Bears Say
Top‑line WeaknessRevenue has been flat to declining with a ~4% drop in FY26 and multi‑year stagnation. Persistent top‑line weakness limits operating leverage, constrains absolute earnings growth potential and forces reliance on M&A, pricing actions and promotions to restore organic momentum over the medium term.
Operational Supply RiskMaterial production and shipping disruptions for Clear Eyes and Pillar5 caused meaningful sales volatility. Manufacturing ramp timing remains uncertain; ongoing operational and logistics risk can suppress recovery, strain retailer relationships and create recurring quarter‑to‑quarter revenue swings.
Near‑term Leverage IncreaseFinancing the Breathe Right purchase pushes pro‑forma leverage toward ~4x at close, raising covenant and refinancing risk until planned deleveraging. Higher leverage reduces financial flexibility, making future M&A, buybacks and integration outcomes dependent on sustained free cash flow and execution.
Prestige Consumer Healthcare News
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $42.62 and its highest was $85.57 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $2.25B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Jul 30, 2026 which is in 48 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on May 13, 2026. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by -$0.16.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of N/A. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 0.88.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,372,166 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $1.23 in its last earnings report, missing expectations of $1.39. Following the earnings report the stock price went down -11.349%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.25 (41.49% Upside)
$82.25 (41.49% Upside)
Blogger Sentiment
Neutral
PBH Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 815.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $225.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.29%
12-Months-Change
Fundamentals
Return on Equity
10.29%
Trailing 12-Months
Asset Growth
2.66%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
PBH Company Deck
PBH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: the call highlighted strong cash generation, margin resilience, strategic M&A (Pillar5, Breathe Right, LaCorium) and digital/channel strengths (e‑commerce ~18%), which position the company for medium‑term upside. However, significant near‑term execution risks—chiefly Clear Eyes supply disruptions, production ramp uncertainty, and shipping disruptions from geopolitical events—drove fiscal '26 revenue declines and create short‑term volatility. Management provided cautious fiscal '27 guidance that assumes improvement in the back half of the year and emphasized deleveraging after acquisitions.View all PBH earnings summariesPBH Stock 12 Month Forecast
Average Price Target
$82.25
▲(41.49% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
McKesson
―
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
1.41% Insiders
45.68% Mutual Funds
10.23% Other Institutional Investors
13.92% Public Companies and
Individual Investors